Xerxes Blood Test And Insurance Fraud Plan

The Xerxes blood-testing and insurance scheme turns the record of industrial illness into evidence of a second injury: Humboldt Chemical and its associates gathered detailed information about workers’ health while failing to use it to warn them or establish their rights. Blood records from hundreds of employees charted changes consistent with serious disease, but the company treated such data as a means of forecasting expenses and workforce turnover. At the same time, insurance arrangements were manipulated to preserve the company’s insurability and limit scrutiny. The scheme’s exposure connects the slow emergence of occupational illness to the legal and financial structures that made it difficult for workers to obtain recognition or compensation.

Exposure and the developing medical record

Xerxine was a chlorinated-hydrocarbon solvent used in industrial processes. During its manufacture, vapors could enter the air; exposure affected the liver, kidneys, and central nervous system. When Humboldt Chemical began making Xerxine in the 1950s, the dangers were not well understood and the plant did not adequately control the vapors. Growing attention to environmental and occupational health in the 1960s and 1970s led to tighter controls, including air scrubbers and better-sealed pipes. By the late 1970s, Xerxes had reduced airborne concentrations to the federal standard of fifty parts per million. That later standard, however, did not undo earlier exposure.

The records eventually examined by Dr. Christophersen covered approximately five hundred Xerxes employees from 1955 to 1982. They tracked blood measures including creatinine, blood urea nitrogen, bilirubin, hematocrit, hemoglobin, and white-cell counts. Taken together, the changes were consistent with renal, liver, and bone-marrow dysfunction. They offered a detailed medical history across decades, not a single snapshot of illness.

Louisa Djiak’s records showed that kidney damage was already noticeable in 1967 and severe by 1969. Around 1979, she began experiencing diffuse symptoms, including itching, fatigue, and headaches, but interpreted them as possibly related to menopause and did not seek medical care. She first saw a doctor in 1984, after her daughter insisted; by then, her chronic renal failure had progressed to an acute stage. Other complications made her a poor candidate for a transplant. Steve Ferraro’s records likewise showed a history consistent with Xerxine exposure; he died of aplastic anemia in 1983. The records and clinical follow-up supported a connection between exposure and illness, while the story also preserves the distinction between evidence consistent with poisoning and proof of legal causation.

Insurance pressure and the use of health data

The financial problem surfaced when the company’s health claims rose. Humboldt Chemical knew that too many employees were making claims and losing work time. Premiums climbed sharply, and Ajax Assurance dropped the company after finding that its claims were too high. Humboldt needed another carrier, but the health data threatened to make the company appear uninsurable.

The company began blood studies, but Curtis Chigwell later explained that the data were not used to establish that workers’ illnesses were caused by their jobs. He described their purpose as projecting medical expenses and likely workforce turnover. The distinction was central: records precise enough to chart developing illness were treated internally as cost information, not as a basis for telling employees that they might be sick or that their conditions could be work-related.

A 1963 letter revealed that Jurshak & Parma had become fiduciaries for Humboldt Chemical’s Xerxes plant and had sent Mariners Rest Life Assurance Company an actuarial study. The study said Xerxes’s losses were comparable to those of other area companies and requested similar rate consideration. Read alongside the later account of the insurance crisis, the document suggested that the company’s relationship with its fiduciary had helped manage how its risks appeared to insurers. V. I. Warshawski suspected that the arrangement could have secured the company a better insurance package than the one employees were offered, with coverage limits affecting which tests or hospital costs workers believed they could claim. That reconstruction remained an inference rather than a fully demonstrated account of every policy or claim.

Chigwell said that some employees did receive proper life or health coverage, enough to discourage the wrong people from asking questions. Louisa was among those covered; he attributed that exception to Jurshak’s claim that he knew her family and felt obliged to look after her. The selective provision of benefits sharpened the contrast between individual exceptions and a company-wide system shaped by rising claims, concern about insurability, and limited disclosure.

Workers’ compensation and the limits of proof

The medical and insurance story was preceded by a failed compensation case. Pankowski and Steve Ferraro, both long-time Humboldt Chemical employees, approached their lawyer in early 1983 after becoming gravely ill and unable to work. Ferraro had worked at the plant since 1959 and Pankowski since 1961. They had left their jobs when illness made continued work impossible and, as a result, could not collect disability benefits. Their lawyer believed they might at least qualify for workers’ compensation if their illnesses were recognized as job-related.

The lawyer first approached the company. When Humboldt refused to cooperate, he filed suit and sought to move quickly because he did not know how long either client would live. A successful case after their deaths could still have brought indemnity payments to their families; the account notes that Illinois insurers paid a quarter of a million dollars to families of workers who died on the job. The possibility of financial relief made the effort consequential even if the men did not survive to see a victory.

Humboldt successfully contested causation. Both men smoked; Pankowski also drank heavily; and both had lived in South Chicago, where the surrounding air offered another possible explanation for illness. The company argued that Xerxine could not be proved to be the cause rather than smoking or general pollution. It also argued that the men had worked at the plant before Xerxine’s toxicity was known, and that the plant had operated according to the medical knowledge then available. The court case was lost, and an appellate lawyer found no viable basis for an appeal. The long-running blood data later made the workers’ illnesses harder to dismiss as isolated misfortune, but did not erase the evidentiary obstacles that had defeated their suit.

After the case, while an appeal was being considered, the lawyer received a threatening telephone call. The caller did not name the case, referring only in general terms to the dangers of using the appellate system. The lawyer pursued possible grounds for appeal, but found none. The threat did not supply a legal remedy; it added intimidation to a case already weakened by disputed causation and the timing of exposure.

Concealment, complicity, and disclosure

The investigation of the records also revealed Curtis Chigwell’s part in their history. After years of working with Xerxes blood tests, he had failed to tell workers that he thought they might be becoming ill. Questions about the compensation case frightened him, and the prospect of reporters learning the truth intensified his fear of malpractice claims and humiliation. When an attempted suicide failed, Art Jurshak contacted him. Chigwell said Jurshak offered to have evidence against him suppressed if he provided limited assistance.

Humboldt had instructed Chigwell to help, and Chigwell said the request concerned insurance. As claims mounted and Ajax Assurance withdrew, Jurshak was used as fiduciary in an effort to make the company appear insurable to another carrier. Chigwell insisted that the blood data did not establish causality; its stated function was to calculate projected medical costs and worker turnover. His account exposed the gulf between possessing a record of illness and acting on its implications for the people whose blood had been tested.

Chigwell’s assistance extended beyond insurance information. He agreed to sedate Louisa Djiak and look after her at the plant for several hours; the account identifies a fatal injection as a further step in the events surrounding her. That episode shows how the insurance scheme intersected with the immediate danger facing an individual worker, rather than remaining an abstract matter of premiums and actuarial reports.

The scheme’s disclosure changed the scale of the case. Dr. Christophersen’s review of Chigwell’s notebooks and her checks with doctors supplied medical interpretation of the blood histories, while Warshawski pressed Frederick Manheim to consider organizing claims for hundreds of former employees and possibly current ones. She warned that such work would require a larger practice and a sustained fight against powerful opposing interests. Manheim agreed to take it on, saying he could not live with himself if he declined a chance to pursue the case. The records that had once been used to project costs could now support an effort to seek redress.

Significance

The scheme depends on a recurring separation: the company could measure changes in workers’ bodies without treating those changes as a responsibility to warn them, and it could collect information useful to its own financial planning without establishing a compensable cause of illness. The blood tests do not simply resolve the case; their careful histories make visible what the earlier lawsuit could not prove to the court, while also clarifying the limits of the data Chigwell said the company intended to use.

Insurance operates here as more than a backdrop to industrial illness. Rising claims threatened the company’s access to coverage, a fiduciary relationship helped shape how its risks were presented, and employees’ access to benefits could vary even as the company accumulated evidence of widespread health problems. The failed compensation action, the threatened appeal, and the later plan to represent hundreds of workers trace the consequences of that arrangement from individual disease to collective legal action. What began as a record of medical change becomes a record of institutional choice: which risks were counted, which harms were disclosed, and who was expected to bear the cost.